OBX · Obsidian Therapeutics, Inc.
Market Cap
$1.06B
Shares
61.77M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$0
FY2025
Net Income
-$100.61M
-21.1%
FY2025
Diluted EPS
-$7.22
-11.6%
FY2025
Operating Cash Flow
-$90.39M
-20.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2025 | FY2024 |
|---|---|---|
| $0 | $0 | |
| $86.11M | $73.19M | |
| $19.55M | $18.07M | |
| $105.67M | $91.26M | |
| -$105.67M | -$91.26M | |
| $5.06M | $8.15M | |
| -$100.61M | -$83.11M | |
| $0 | $0 | |
| -$100.61M | -$83.11M | |
| -$100.56M | -$83.16M | |
| USD/shares | -$7.22 | -$6.47 |
| USD/shares | -$7.22 | -$6.47 |
| shares | 13.94M | 12.85M |
| shares | 13.94M | 12.85M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Coverage backlog: 2 eligible filings and 0 covenant artifacts have no current-version terminal extraction result. This includes untouched sources and sources on the retry ladder.
No terminal debt extraction result is available yet; this is not evidence that the company has no debt.